Overview

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Status:
Terminated

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the effectiveness between CAELYX and topotecan hydrochloride (HCl) in Chinese participants with recurrent epithelial ovarian carcinoma following failure of first-line, platinum-based chemotherapy, who have received no more than one prior platinum-based regimen therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Xian-Janssen Pharmaceutical Ltd.

Treatments:

Doxorubicin
Liposomal doxorubicin
Topotecan